Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

References

• DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008 Nov 1;68(21):8643–8653.
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez AJ. Rituximab: an insider’s historical perspective. Semin Oncol. 2000 Dec;27(6 Suppl 12):9–16.
   PubMed Web of Science ®Google Scholar
• Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev. 2000 Aug;26(4):269–286.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018 Mar 23;359(6382):1350–1355.
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018 Jul 5;379(1):64–73.
   PubMed Web of Science ®Google Scholar
• Mathé G, Tran Ba LO, Bernard J. [Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts]. C R Hebd Seances Acad Sci. 1958 Mar 10; 246(10):1626–1628.
   PubMedGoogle Scholar
• Ghose T, Nigam SP. Antibody as carrier of chlorambucil. Cancer. 1972 May;29(5):1398–1400.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Preston DF, Primus FJ, et al. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 1974 Jan;34(1):1–9.
   PubMed Web of Science ®Google Scholar
• Moolten FL, Capparell NJ, Zajdel SH, et al. Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40. J Natl Cancer Inst. 1975 Aug;55(2):473–477.
   PubMedGoogle Scholar
• Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978 Jun 22;298(25):1384–1386.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Gaffar SA, Bennett SJ, et al. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res. 1981 Nov;41(11 Pt 1):4354–4360.
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Bischof WK, Hibi N, et al. Effect of a conjugate of daunomycin and antibodies to rat alpha-fetoprotein on the growth of alpha-fetoprotein-producing tumor cells. Proc Natl Acad Sci U S A. 1982 Jan;79(2):621–625. .
   PubMed Web of Science ®Google Scholar
• Vitetta ES, Krolick KA, Uhr JW. Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev. 1982;62(1):159–183.
   PubMedGoogle Scholar
• Sharkey RM, Pykett MJ, Siegel JA, et al. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res. 1987 Nov 1;47(21):5672–5677.
   PubMed Web of Science ®Google Scholar
• Shih LB, Sharkey RM, Primus FJ, et al. Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. Int J Cancer. 1988 Jun 15;41(6):832–839.
   PubMed Web of Science ®Google Scholar
• Senter PD, Saulnier MG, Schreiber GJ, et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842–4846. .
   PubMed Web of Science ®Google Scholar
• Ghetie MA, May RD, Till M, et al. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 1988 May 1;48(9):2610–2617.
   PubMed Web of Science ®Google Scholar
• Weiner LM, O’Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 1989 Jul 15;49(14):4062–4067.
   PubMed Web of Science ®Google Scholar
• Elias DJ, Hirschowitz L, Kline LE, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res. 1990 Jul 1;50(13):4154–4159.
   PubMed Web of Science ®Google Scholar
• Petersen BH, DeHerdt SV, Schneck DW, et al. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 1991 May 1;51(9):2286–2290.
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005 Sep;23(9):1137–1146.
   PubMed Web of Science ®Google Scholar
• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010 Aug;14(4):529–537.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315–337.
   PubMed Web of Science ®Google Scholar
• Abe Y, Sugahara K, Nakada T, et al. ADCs on the market and in clinical development. In: Matsummura Y, Tarin D, editors. Cancer drug delivery systems based on the tumor microenvironment. Japan KK: Springer; 2019; p.155–174.
   Google Scholar
• Leung D, Wurst JM, Liu T, et al. Antibody conjugates-Recent advances and future Innovations. Antibodies (Basel). 2020 Jan 8;9(1):E2.  doi:10.3390/antib9010002
   PubMedGoogle Scholar
• Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 1;19(13):3244–3254.
   PubMed Web of Science ®Google Scholar
• Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010 Apr 20;28(12):2085–2093.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003 Jul;21(7):778–784.
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4;363(19):1812–1821.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011 Feb 1;29(4):398–405.
   PubMed Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010 Jun 1;28(16):2698–2704.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783–1791.
   PubMed Web of Science ®Google Scholar
• Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173–185.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020 Feb 13;382(7):610–621.
   PubMed Web of Science ®Google Scholar
• Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):827–836.
   PubMed Web of Science ®Google Scholar
• Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816–826.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019 May;6(5):e254–e265.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015 Jun;16(6):704–715.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019 Jul;20(7):998–1010.
   PubMed Web of Science ®Google Scholar
• Hanna KS. Clinical overview of enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. Drugs. 2020 Jan;80(1):1–7.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019 Oct 10;37(29):2592–2600.
   PubMed Web of Science ®Google Scholar
• Dan N, Setua S, Kashyap VK, et al. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel). 2018 Apr 9;11:32.
   PubMedGoogle Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Aug;32(8):1768–1777.
   PubMed Web of Science ®Google Scholar
• Birrer MJ, Moore KN, Betella I, et al. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019 Jun 1;111(6):538–549.
   PubMedGoogle Scholar
• Lucas AT, Robinson R, Schorzman AN, et al. Pharmacologic considerations in the disposition of antibodies and antibody-drug conjugates in preclinical models and in patients. Antibodies (Basel). 2019 Jan 1;8:3.
   PubMedGoogle Scholar
• Kadcyla (prescribing information). San Francisco, CA: Genentech; 2019.
   Google Scholar
• Powell CA, Camidge DR, Gemma A, et al. Characterization, monitoring, and management of interstitial lung disease in patients with metastatic breast cancer: analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload. San Antonio, Texas, USA: San Antonio Breast Cancer Symposium. 2018:Abstract P6-17-06.
   Google Scholar
• Coats S, Williams M, Kebble B, et al. Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res. 2019 Sep 15;25(18):5441–5448.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Molina A. Investigational antibody-drug conjugates for treatment of B-lineage malignancies. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):452–468.e4.
   PubMed Web of Science ®Google Scholar
• Lambert J, Pautas C, Terre C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019 Jan;104(1):113–119.
   PubMed Web of Science ®Google Scholar
• Oak E, Bartlett NL. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Expert Opin Drug Saf. 2016 Jun;15(6):875–882.
   PubMed Web of Science ®Google Scholar
• Masters JC, Nickens DJ, Xuan D, et al. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018 Feb;36(1):121–135.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006 Jul-Aug;56(4):226–243.
   PubMed Web of Science ®Google Scholar
• Lipinski M, Parks DR, Rouse RV, et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981;78(8):5147–5150.
   PubMed Web of Science ®Google Scholar
• Cubas R, Li M, Chen C, et al. Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796(2):309–314.
   PubMed Web of Science ®Google Scholar
• Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015 Mar;6(3–4):84–105.
   PubMedGoogle Scholar
• Stein R, Basu A, Chen S, et al. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer. 1993 Dec 2;55(6):938–946.
   PubMed Web of Science ®Google Scholar
• Basu A, Goldenberg DM, Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer. 1995 Aug 9;62(4):472–479.
   PubMed Web of Science ®Google Scholar
• Stein R, Basu A, Goldenberg DM, et al. Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7. Int J Cancer Suppl. 1994;8:98–102.
   PubMedGoogle Scholar
• De Leij L, Helrich W, Stein R, et al. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer Suppl. 1994;8:60–63.
   PubMedGoogle Scholar
• Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018 Jun 22;9(48):28989–29006.
   PubMedGoogle Scholar
• Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. mAbs. 2019 Aug/Sep;11(6):987–995.
   PubMed Web of Science ®Google Scholar
• Shih LB, Xuan H, Aninipot R, et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res. 1995 Dec 1;55(23 Suppl):5857s–5863s.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Cardillo TM, Goldenberg DM. Chapter 8: topoisomerase inhibitors as antibody-drug conjugate payloads. In: Thurston DE, Jackson PJM, editors. Cytotoxic Payloads for Antibody-Drug Conjugates. Drug Discovery. Cambridge (UK): Royal Society of Chemistry; 2019. p. 164–184.
   Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002 Mar;8(3):641–661.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7(8):2182–2194.
   PubMed Web of Science ®Google Scholar
• Thomas A, Pommier Y. Targeting topoisomerase I in the era of precision medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581–6589.
   PubMed Web of Science ®Google Scholar
• Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013 Jan 18;8(1):82–95.
   PubMed Web of Science ®Google Scholar
• Haggerty TJ, Dunn IS, Rose LB, et al. Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. Cancer Immunol Immunother. 2011 Jan;60(1):133–144.
   PubMed Web of Science ®Google Scholar
• Wan S, Pestka S, Jubin RG, et al. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One. 2012;7(3):e32542.
   PubMed Web of Science ®Google Scholar
• McKenzie JA, Mbofung RM, Malu S, et al. The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy. J Natl Cancer Inst. 2018 Jul 1;110(7):777–786.
   PubMedGoogle Scholar
• Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015 May 20;26(5):919–931.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015 Sep 08;6(26):22496–22512.
   PubMedGoogle Scholar
• Moon SJ, Govindan SV, Cardillo TM, et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008 Nov 13;51(21):6916–6926.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Cardillo TM, Moon SJ, et al. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009 Oct 1;15(19):6052–6061.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res. 2015 Nov 15;21(22):5131–5138.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157–3169.
   PubMed Web of Science ®Google Scholar
• Bignotti E, Ravaggi A, Romani C, et al. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Int J Gynecol Cancer. 2011 Dec;21(9):1613–1621.
   PubMed Web of Science ®Google Scholar
• Raji R, Guzzo F, Carrara L, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011 Nov 10;30:106.
   PubMed Web of Science ®Google Scholar
• Varughese J, Cocco E, Bellone S, et al. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Am J Obstet Gynecol. 2011 Dec;205(6):567.e1-7.
   PubMed Web of Science ®Google Scholar
• Perrone E, Manara P, Lopez S, et al. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Mol Oncol. 2020 Mar;14(3):645–656.
   PubMed Web of Science ®Google Scholar
• Lin H, Zhang H, Wang J, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014;134(5):1239–1249.
   PubMed Web of Science ®Google Scholar
• Liu J, Yang D, Yin Z, et al. A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo. Biochem Biophys Res Commun. 2019 Mar 14;512(2):276–282.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Mostafa AA, Rossi DL, et al. Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51. Cancer Res. 2017;77(13Supplement):abstract3193.
   Google Scholar
• Arnaudeau C, Helleday T, Jenssen D. The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. J Mol Biol. 1999 Jun 25;289(5):1231–1238.
   PubMed Web of Science ®Google Scholar
• Arnaudeau C, Rozier L, Cazaux C, et al. RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors. Nucleic Acids Res. 2001 Feb 1;29(3):662–667.
   PubMed Web of Science ®Google Scholar
• Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017 Dec 5;117(12):1736–1742.
   PubMed Web of Science ®Google Scholar
• Morton CL, Wierdl M, Oliver L, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res. 2000 Aug 1;60(15):4206–4210.
   PubMed Web of Science ®Google Scholar
• Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010 Jan;2(1):51–63.
   PubMedGoogle Scholar
• Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002 Sep;72(3):265–275.
   PubMed Web of Science ®Google Scholar
• Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol. 2002;20(15):3293–3301.
   PubMed Web of Science ®Google Scholar
• Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017 Oct 01;123(19):3843–3854.
   PubMed Web of Science ®Google Scholar
• Zhao H, Lee C, Sai P, et al. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization 1. J Org Chem. 2000;65(15):4601–4606.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Govindan SV, Cardillo TM, et al. Selective and concentrated accretion of SN-38 with a CEACAM5-targeting antibody-drug conjugate (ADC), labetuzumab govitecan (IMMU-130). Mol Cancer Ther. 2018 Jan;17(1):196–203.
   PubMed Web of Science ®Google Scholar
• Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015 Sep 01;21(17):3870–3878.
   PubMed Web of Science ®Google Scholar
• Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017 Jul 01;35(19):2141–2148.
   PubMed Web of Science ®Google Scholar
• Gray JE, Heist RS, Starodub AN, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res. 2017 Oct 01;23(19):5711–5719.
   PubMed Web of Science ®Google Scholar
• Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017 Aug 20;35(24):2790–2797.
   PubMed Web of Science ®Google Scholar
• Starodub AN, Ocean AJ, Messersmith WA, et al. Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): phase I/II clinical experience. J Clin Oncol. 2015;33(supple):Abstr3546.
   Google Scholar
• Faltas B, Goldenberg DM, Ocean AJ, et al. Sacituzumab govitecan, a novel antibody-drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e75–9.
   PubMed Web of Science ®Google Scholar
• Bardia A, Vahdat LT, Diamond JR, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as 3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results. San Antonio, Texas, USA: San Antonio Breast Cancer Symposium. 2017:abstract GS1–07.
   Google Scholar
• Tagawa ST, Faltas B, Lam E, et al. Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial cancers (UC): interim results. Annals of Oncology. 2017;28(Supplement5):301(abstract 858P).
   Google Scholar
• Bardia A, Tolaney SM, Juric D, et al. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for endocrine-refractory hormone-receptor positive (HR+) metastatic breast cancer (mBC). J Clin Oncol. 2018;36:Abstr 1004.
   Web of Science ®Google Scholar
• Tagawa ST, Faltas B, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancers (mUC): results from a Phase I/II study. J Clin Oncol. 2019;37(suppl7S):abst354.
   Google Scholar
• Tagawa ST, Petrylak DP, Grivas P, et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. Journal of Clinical Oncology. 2019;37(15_suppl):abstr TPS3153.
   Web of Science ®Google Scholar
• Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019 Feb 21;380(8):741–751.
   PubMed Web of Science ®Google Scholar
• Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009 Feb;9(1):29–33.
   PubMed Web of Science ®Google Scholar
• Sands JM, Shimizu T, Garon EB, et al. First-in-human phase 1 study of DR-1062a in patients with advanced solid tumors. Journal of Clinical Oncology. 2019;37(15_suppl):abstr 9051.
   Google Scholar
• Okajima D, Yasuda S, Yokouchi Y, et al. Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd. Journal of Clinical Oncology. 2018;36(15_suppl):abstract e24206.
   Web of Science ®Google Scholar
• Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010 Mar;46(5):944–953.
   PubMed Web of Science ®Google Scholar
• Varughese J, Cocco E, Bellone S, et al. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol. 2011 Jul;122(1):171–177.
   PubMed Web of Science ®Google Scholar
• Varughese J, Cocco E, Bellone S, et al. Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer. 2011 Jul 15;117(14):3163–3172.
   PubMed Web of Science ®Google Scholar
• Bignotti E, Zanotti L, Calza S, et al. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol. 2012 Nov 14;12(1):22.
   PubMedGoogle Scholar
• Han C, Perrone E, Zeybek B, et al. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecol Oncol. 2020 Feb;156(2):430–438.
   PubMed Web of Science ®Google Scholar
• Zeybek B, Manzano A, Bianchi A, et al. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Sci Rep. 2020 Jan 22;10(1):973.
   PubMed Web of Science ®Google Scholar
• Han C, Bellone S, Schwartz PE, et al. Sacituzumab govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. Gynecologic Oncology Reports. 2018 Aug;25:37–40.
   PubMed Web of Science ®Google Scholar
• Dotan E, Cohen SJ, Starodub AN, et al. Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017 Oct 10;35(29):3338–3346.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Cardillo TM, Sharkey RM, et al. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther. 2013 Jun;12(6):968–978.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Govindan SV, Cardillo TM, et al. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224–234.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Zalath MB, et al. IMMU-140, a novel SN-38 antibody-drug conjugate targeting HLA-DR, mediates dual cytotoxic effects in hematologic cancers and malignant melanoma. Mol Cancer Ther. 2018 Jan;17(1):150–160.
   PubMed Web of Science ®Google Scholar
• Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019 Oct;148:104398.
   PubMed Web of Science ®Google Scholar
• Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007 May 1;109(9):1721–1728.
   PubMed Web of Science ®Google Scholar
• Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov 15;118(22):5463–5472.
   PubMed Web of Science ®Google Scholar
• Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010 Dec;33(6):637–645.
   Google Scholar
• Bonotto M, Gerratana L, Iacono D, et al. Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines? The Oncologist. 2015 Jul;20(7):719–724.
   PubMed Web of Science ®Google Scholar
• den Brok WD, Speers CH, Gondara L, et al. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat. 2017 Feb;161(3):549–556.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019 Feb;9(2):176–198.
   PubMed Web of Science ®Google Scholar
• Sussman D, Smith LM, Anderson ME, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991–3000.
   PubMed Web of Science ®Google Scholar
• Modi S, Pusztai L, Forero A, et al. Abstract PD3-14: phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer. Cancer Res. 2018;78(4Supplement):PD3-14.
   Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):44–59.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Sharkey RM, Rossi DL, et al. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin Cancer Res. 2017 Jul 01;23(13):3405–3415.
   PubMed Web of Science ®Google Scholar
• Yver A, Agatsuma T, Soria JC. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers. Ann Oncol. 2020;31(3):430–434..
   PubMed Web of Science ®Google Scholar
• Haratani K, Yonesaka K, Takamura S, et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest. 2020 Jan 2;130(1):374–388.
   PubMed Web of Science ®Google Scholar
• Collins DM, Bossenmaier B, Kollmorgen G, et al. Acquired resistance to antibody-drug conjugates. Cancers (Basel). 2019 Mar 20;11(3):394.
   Web of Science ®Google Scholar
• Chang CH, Wang Y, Zalath M, et al. Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers. Mol Cancer Ther. 2016 Aug;15(8):1910–1919.
   PubMed Web of Science ®Google Scholar
• Winau F, Westphal O, Winau R. Paul Ehrlich–in search of the magic bullet. Microbes Infect. 2004 Jul;6(8):786–789.
   PubMed Web of Science ®Google Scholar